| Medigene Limited Patent applications |
| Patent application number | Title | Published |
|---|
| 20100331342 | Immuno Inhibitory Pyrazolone Compounds - Compounds of formula (IA) or (IB) are inhibitors of CD80 and useful in immunomodulation therapy: wherein Ar represents an optionally substituted monocyclic or bicyclic aromatic or heteroaromatic group having from 5 to 10 ring atoms; R | 12-30-2010 |
| 20090312334 | Immunomodulating Heterocyclic Compounds - Compounds of formula (I) are inhibitors of CD80 and useful in immunomodulation therapy: | 12-17-2009 |
| 20090221590 | SALT OF CD 80 ANTAGONIST - The choline salt of the CD80 antagonist compound 4-(6-fluoro-3-oxo-1,3-dihydro-pyrazolo[4,3-c]cinnolin-2-yl)-N-(2,2-difluoro-ethyl)-benzamide (I) has good aqueous solubility and is therefore convenient for pharmaceutical use. | 09-03-2009 |
| 20090208447 | Polypeptides - The present invention provides polypeptides having the property of binding to a given Class I pMHC CHARACTERISED IN THAT said polypeptide has a K | 08-20-2009 |
| 20090105133 | Gamma-Delta T Cell Receptors - The present invention provides gamma-delta T cell receptors (γδTCRs) with an introduced disulfide interchain bond. Such proteins, and cells expressing of such proteins on the surface thereof, have value in methods for distinguishing between cell populations by the TCR ligand they present, and in the treatment of diseases. | 04-23-2009 |
| 20090054257 | METHOD OF IMPROVING T CELL RECEPTORS - A method of increasing the affinity and/or decreasing the off-rate of a given TCR specific for a given target pMHC, comprising creating a plurality of TCRs having an α chain CDR2 sequence and/or a β chain CDR2 sequence different from the corresponding CDR2 sequence(s) of the given TCR but having the same α and β CDR1 and CDR3 sequences as the given TCR, determining the affinity and/or off-rate of members of said plurality of TCRs for the target pMHC, and selecting one or more members having at least a 10-fold greater affinity for the target pMHC than the given TCR and/or a 10-fold slower off-rate for the target pMHC than the given TCR. | 02-26-2009 |
| 20080292602 | T Cell Receptors Which Specifically Bind to Vygfvracl-Hla-A24 - The present invention provides isolated T cell receptors (TCRs) having the property of specifically binding to the VYGFVRACL-HLA-A24 peptide-MHC. Such TCRs are useful, either alone or associated with a therapeutic agent, for targeting cancerous cells presenting the complex. | 11-27-2008 |
| 20080292549 | High Affinity Melan-A T Cell Receptors - The present invention provides TCRs having an affinity (K | 11-27-2008 |
